Clinical Trial Search

Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…

Primary: Change in Neurocognitive Functioning — -0.94; -0.81; -1.03; -0.51 Global Neurocognitive Z-Score — p=0.05

Primary: Neuropsychological Status (i.e., Cognitive Functioning) — 0.008; .484; -.084; -.482 z-score composites of cognitive domains — p=0.001

Primary: Feasibility - Session Attendance — 5; 5 Participants

Primary: Working Memory Assessed by Domain Deficit Score — .29; .21; .14; .26 Score on a scale — p=0.039

Primary: Change in Normalized Composite Neurocognitive Test Score at Week 48 From Baseline — 0.20; 0.26; 0.31 total neurocognitive z-score — p=0.60

Primary: Change in Working Memory — 51.33; 43.15 mean T score on working memory tests — p=.013

Primary: Change From Baseline to Week 24 in Global Neuropsychological Performance — .24 units on a scale — p=0.0079

Primary: Psychomotor Speed — 54.2; 60.4; 53.4 score on a scale — p=0.40

Primary: Change From Week 0 in Percentage of Blood Monocytes Expressing Surface Marker CD16 at 12 Weeks, as a Result of Treatment. — 1.14; 1.51 Fold change — p=0.39

Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants

Primary: Change in the Processing of Speed — 2.63; 6.06 units on a scale

Primary: Percentage of Participants Completing the Study — 90 Percentage of participants

Primary: Cognitive Function, Global Cognitive Score (Z-score) — 0.15; 0.19; 0.16; 0.25 z score — p=0.68

Primary: Self-Perceived Need for Cognitive Training — 7.49; 3.34 score on a scale

Primary: Change From Baseline to 24 Weeks in HIV DNA (Log-10 Copies/10^6 Cells) as Measured by HIV DNA Within CD14+ Peripheral Blood Mononuclear Cells — 0.58 Log-10 copies/10^6…

Primary: Influx Constant (Ki) for 18F-FDOPA PET. — 0.01415; 0.01409; 0.01588; 0.01592 min-1

Primary: Association of 11C-labelled PK11195 Uptake Using PET With Acute HCV and HIV Infection — 0.18; 0.22 binding potential ratio

Primary: Change in hsCRP Levels at 24 Weeks — 2.19; 4.47 mg/L — p=0.607

Primary: Number of Participants With Chronic Myogenic Pain, TMJ Disoder, and Burning Mouth Syndrome — 72; 8; 37; 7 Participants

Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244

Primary: Change in Neurometabolites Based on Magnetic Resonance Spectroscopy (MRS) — 19.61; 24.54; 6.71; 12.08 arbitrary units

Primary: Neuropsychological Performance Change — -0.27; -0.17 units on a scale

Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants

Primary: Stroop Color and Word Test Score — 31.17; 28.89; 32.87; 30.69 number of correct responses

Primary: Total Doravirine Concentrations in Cerebrospinal Fluid — 58.6 ng/ml

Primary: Neurocognition: Mean Score of Hopkins Verbal Learning Test (Total) at Baseline — 29.4; 31.1 score on a scale

Primary: Neuropsychological Performance (KABC2) — 63.32; 61.13; 62.65 T scores from USA norms for this test — p=0.02

Primary: Interleukin 6 (IL-6) Biological Markers — 2.24; 2.63; 2.53; 2.88 pg/mL

Primary: Neuropathic Element of Pain Using the Doleur Neuropathique 4 Interview — 81; 67 Participants